As malaria remains a major public health concern in Nigeria, Geneith Pharmaceuticals Limited has reiterated its commitment to providing reliable treatment options while urging responsible drug use to ensure effective outcomes.
In a statement signed by the company’s Chairman, Chief Emmanuel Umenwa, and released to the media, Pharm. Abimbola Bowoto, Assistant General Manager, Sales and Marketing at Geneith Pharmaceuticals, noted that while progress has been made in malaria control, challenges persist due to emerging drug-resistant strains and widespread misuse of medications, often fuelled by misconceptions about side effects.
Bowoto explained that side effects—whether mild or rare—are a normal aspect of medicine use worldwide. What matters most, he stressed, is adherence to medical advice, which reduces risks and enhances therapeutic benefits. This principle, he said, applies equally to antimalarial therapies such as Camosunate, a trusted Artemisinin-based Combination Therapy (ACT) combining Artesunate and Amodiaquine.
“Camosunate remains one of Nigeria’s most dependable ACTs for uncomplicated malaria, in full alignment with World Health Organization (WHO) recommendations. Its proven efficacy lies in its ability to clear parasites rapidly, relieve symptoms promptly, and offer extended protection due to the long half-life of Amodiaquine,” Bowoto stated.
He referenced a 2013 clinical study conducted at the University of Benin Teaching Hospital (UBTH), which affirmed Camosunate’s effectiveness and safety in both adult and paediatric patients. The review reported high cure rates, minimal side effects, and strong compliance when the product was used as recommended—further establishing its role as a frontline treatment option in Nigeria.
The study also highlighted improved outcomes when Camosunate was taken with meals and adequate hydration—advice that aligns with Geneith’s product guidelines and patient information leaflets. Bowoto emphasized that most side effects occur when patients fail to follow usage directions. Taking Camosunate after food with sufficient water enhances absorption and minimizes discomfort, he added.
Designed with patient convenience in mind, Camosunate ACT offers age-specific dosing, including vanilla-flavoured granules for children and a simple three-day regimen for adults and older children—features that have made it a preferred choice among healthcare professionals.
Bowoto reaffirmed Geneith’s dedication to integrity, commitment, and innovation, which continue to drive its pursuit of excellence in quality and safety. Through secure packaging and advanced traceability systems, the company ensures that patients receive only genuine, effective medicines that meet regulatory and clinical standards.
He concluded by calling for stronger public awareness on proper medicine use, urging healthcare providers to continue prescribing WHO-compliant ACTs like Camosunate and advising patients to always complete their treatment courses to prevent relapse and drug resistance.
“Geneith’s mission goes beyond producing medicines; it is about protecting trust, advancing innovation, and standing firmly with healthcare professionals and communities in the fight against malaria,” Bowoto affirmed.
